US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Spago Nanomedical strengthened management to reflect project progress

The clinical phase I/IIa study evaluating radiopharmaceutical candidate 177Lu-SN201 in solid tumours has been progressing steadily for Spago Nanomedical. This progress has led the company to put more focus on regulatory priorities. As part of this, the company recently strengthened its management team by adding Birgitta Rembratt Svensson as Head of CMC and Supply. BioStock reached out to Birgitta to learn more about her role and how it complements the company’s new phase of development.Read the interview with Birgitta Rembratt Svensson at biostock.se:https://www.biostock.se/2024/09/spago-

BioStock: Spago’s CEO - "Advancing the Tumorad programme comes first"

Spago Nanomedical’s Q1 report signals steady progress with its radiopharma pipeline. Lead programme Tumorad recently got a boost by the release of positive non-clinical data in a triple-negative breast cancer model, incentivising the company to strengthen its management. – 2024 has begun in the same positive spirit as we ended last year. Given the progress within both of our development programmes, we have seen a need to strengthen the company's organisation, says Spago’s CEO Mats Hansen.Read the article at biostock.se: Spago’s CEO: Advancing the Tumorad programme comes first -

BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”

Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer. The deal showcases rising interest in the field of radiopharmaceuticals. BioStock got in touch with Mats Hansen, CEO of Swedish radiopharma company Spago Nanomedical to get his take on the deal and where Spago is in its development of lead programme Tumorad.Read the article at biostock.se: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding” - BioStock 

BioStock: 2023 springboard for Spago’s radionuclide cancer therapy

In 2023, Swedish biotech Spago Nanomedical kicked off its journey in the clinic with radionuclide cancer therapy Tumorad. Ending the year with the first patient dosed in the phase I trial and a SEK 30.6 million capital raise, Spago has strong momentum going into 2024. BioStock spoke with Spago’s CEO Mats Hansen to hear about the progress made in 2023 and what he is most looking forward to this year.Read the interview with Mats Hansen at biostock.se: 2023 springboard for Spago’s radionuclide cancer therapy - BioStock 

BioStock: Spago’s phase I/IIa cancer trial progressing steadily

The positive momentum for Spago Nanomedical carries over into 2024 as the company announces continued progress with its Tumorad phase I/IIa trial. The independent data monitoring committee has recommended a dose escalation with the company’s radiopharmaceutical drug candidate 177Lu-SN201 for the treatment of advanced cancer.Read the article at biostock.se: Spago’s phase I/IIa cancer trial progressing steadily - BioStock This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Positive data in Spago’s phase IIa endometriosis trial

Spago Nanomedical has announced positive top line data from a clinical phase IIa study in patients with endometriosis. SPAGOPIX-02 study is evaluating the MRI-enhancing effect of the contrast agent pegfosimer manganese. The data confirms that the primary endpoint was met, without compromising safety. BioStock reached out to Spago's Chief Executive Officer Mats Hansen to learn more.Read the interview with Mats Hansen at biostock.se: Positive data in Spago’s phase IIa endometriosis trial - BioStock 

BioStock: First patient dosed in Spago’s phase I/IIa trial

Spago Nanomedical recently received approval to start the phase I/IIa study with Tumorad in Australia. The study is now well on its way as the company announced last week that the first patient has been successfully dosed. BioStock reached out to Spago's Chief Development Officer Paul Hargreaves to learn more.Read the interview with Paul Hargreaves at biostock.se: First patient dosed in Spago’s phase I/IIa trial - BioStock  This is a press release from BioStock - Connecting Innovation & Capital. https://

BioStock: Tumorad's potential in transforming cancer care

In an era where cutting-edge science is radically transforming the healthcare landscape, Spago Nanomedical has garnered significant attention with its radionuclide cancer therapy project Tumorad. This initiative aims to provide a ground-breaking alternative in cancer treatment. To learn more about Tumorad’s potential, BioStock reached out to Spago's CEO Mats Hansen for an interview.Read the interview with Mats Hansen at biostock.se: Tumorad's potential in transforming cancer care - BioStock This is a

BioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa

Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago’s CEO Mats Hansen.Read the interview with Mats Hansen at biostock.se: Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock This is a press release from BioStock -

BioStock: Spago Nanomedical’s SAB on Tumorad’s potential

Recently, Spago Nanomedical announced that the company has formed a Scientific Advisory Board for the radiopharmaceutical programme Tumorad. BioStock reached out to Dr Austin Smith to learn more about the field and Tumorad’s potential.Read the interview with Spago Nanomedical's SAB member Dr Austin Smith at biostock.se: https://www.biostock.se/2023/06/spago-nanomedicals-sab-on-tumorads-potential/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

BioStock: Spago Nanomedical's CDO on study submission

Spago Nanomedical recently submitted the application to start the phase I/IIa study with Tumorad in Australia. Spago's Chief Development Officer Paul Hargreaves visited BioStock's studio to talk about the new radionuclide therapy and the upcoming study.Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se: https://www.biostock.se/en/2023/05/spago-nanomedicals-cdo-on-study-submission/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Tumorad clinical start around the corner for Spago Nanomedical

Encouraged by positive preclinical data with Tumorad, Spago Nanomedical has intensified preparations for the upcoming phase I/IIa study in cancer patients. The company also reported advancements with the contrast agent SpagoPix. BioStock reached out to CEO Mats Hansen for a comment on the Q1 report.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2023/05/tumorad-clinical-start-around-the-corner-for-spago-nanomedical/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Spago Nanomedical reports advancement

Lund-based Spago Nanomedical recently published its financial statements for 2022, where the company reports advancement within its projects with the upcoming start of clinical studies in Tumorad and the initiation of the company's first clinical phase II study with SpagoPix. BioStock reached out to CEO Mats Hansen to hear more about the company's ambitions for 2023.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2023/02/spago-nanomedical-reports-advancement/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Spago Nanomedical publishes positive preclinical data

Preclinical data with Spago Nanomedical’s radionuclide therapy concept Tumorad was recently published in the scientific journal ACS Omega. The paper describes the composition, stability and mode of action for the drug candidate [177]Lu-SN201 and concludes that the candidate’s properties are suitable for systemic treatment of cancer. BioStock reached out to CEO Mats Hansen to learn more on what this means for the project.Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2023/01/spago-nanomedical-publishes-positive-preclinical-data/

BioStock Studio: Spago Nanomedical’s CDO on the endometriosis study

First North-listed Spago Nanomedical has recently initiated a phase IIa study with the MRI contrast agent SpagoPix in endometriosis. Paul Hargreaves, Chief Development Officer, visited BioStock’s studio and talked about the disease, the need for better diagnostics and the phase IIa study.Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se: https://www.biostock.se/en/2022/12/spago-nanomedicals-cdo-on-the-endometriosis-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Spago Nanomedical starts phase IIa study in endometriosis

Lund-based Spago Nanomedical has recently been given the go-ahead to initiate a phase IIa study with the product candidate SN132D for the diagnosis of the widespread disease endometriosis. Patient recruitment has already begun and the company expects to be able to include the first patient shortly. BioStock talked to CEO Mats Hansen about the new area and the upcoming study, but also about the SPAGOPIX-01 study in breast cancer that recently was concluded.Read the full interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/12/spago-nanomedical-

BioStock: Spago Nanomedical in hot area

Radionuclide therapies for cancer is a hot area that has been noticed through clinical advances, approved drugs and completed licensing deals. First North-listed Spago Nanomedical is in the process of entering clinical phase with its drug candidate [177]Lu-SN201, which is expected to have wide use in this particular area.Read the article about Spago Nanomedical at biostock.se: https://www.biostock.se/en/2022/09/spago-nanomedical-in-hot-area/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Spago Nanomedical on the autumn newsflow

During the second quarter, Lund-based Spago Nanomedical carried out a rights issue securing financial resources to keep up the pace of the development work with Tumorad, the company's radionuclide treatment for cancer. The company's second project, a new contrast agent for MRI diagnostics, is already in clinical trial. BioStock contacted CEO Mats Hansen for an update on the autumn news flow.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/08/spago-nanomedical-on-the-autumn-newsflow/ This is a press release from BioStock -

BioStock: Spago Nanomedical progresses towards clinical phase with Tumorad

Just before mid-year, Lund-based Spago Nanomedical announced that the company raised 58.4 MSEK in the completed capital round. The proceeds give the company the resources to maintain the pace in its two projects – SpagoPix in cancer diagnostics and Tumorad, in which it is developing a new radionuclide cancer treatment. BioStock reached out to CEO Mats Hansen for comments on recent events and what awaits in the coming six months.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/07/spago-nanomedical-progresses-towards-clinical-phase-

BioStock: Spago Nanomedical on project potential

Lund-based Spago Nanomedical recently published its first interim report of the year and presented the activities from its Spagopix and Tumorad projects. BioStock talked to CEO Mats Hansen about the most important events during the quarter and about the potential of the projects.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/05/spago-nanomedical-on-project-potential/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Spago Nanomedical looks ahead

First North-listed Spago Nanomedical has started the year with positive news from both the SpagoPix and the Tumorad projects. The company's financial status was recently reported when publishing the interim results for the fourth quarter of 2021. BioStock contacted CEO Mats Hansen for a comment and a forward view.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/02/spago-nanomedical-looks-ahead/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Spago Nanomedical on the progress with Tumorad

This week, Lund-based Spago Nanomedical presented positive preclinical data in its cancer treatment project Tumorad. After treatment with the candidate [177]Lu-SN201, a significant reduction in tumour growth was shown in a colorectal cancer model. In addition, the survival was extended by 39 per cent compared to the control group. BioStock contacted CEO Mats Hansen for a comment on the development work with Tumorad.Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2022/01/spago-nanomedical-on-the-progress-with-tumorad/ This is a

BioStock: Positive interim results from Spago Nanomedical

Lund-based company Spago Nanomedical recently announced interim results from their phase I study with SpagoPix, the tumour selective contrast agent in cancer diagnostics with magnetic resonance imaging. The results show that the candidate is safe, that it accumulates into the tumours, and that it provides clear contrast enhancement in the image analysis. Based on these results the company has decided to expand the study to new indications, in addition to breast cancer. BioStock reached out to CEO Mats Hansen for a comment.Read the interview with Spago Nanomedical's CEO Mats Hansen at

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe